EcoDrugPlus

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSOTSG00005025238
Gene Symbol: CYSLTR1
1 Cross references
166 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSOTSG00005013026
Gene Symbol: CYSLTR1
3 Cross references
165 Possible Orthologues:

Cytidine Deaminase A

Ensembl ID : ENSOTSG00005006696
Gene Symbol: CDAA
1 Cross references
151 Possible Orthologues:

Cytidine Deaminase A

Ensembl ID : ENSOTSG00005009774
Gene Symbol: CDAA
1 Cross references
150 Possible Orthologues:

Cytidine Deaminase-Like

Ensembl ID : ENSOTSG00005029527
Gene Symbol: LOC112254156
3 Cross references
196 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSOTSG00005000210
Gene Symbol: CYP19A1
1 Cross references
244 Possible Orthologues:

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSOTSG00005029252
Gene Symbol: CYP26A1
3 Cross references
132 Possible Orthologues:

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSOTSG00005028228
Gene Symbol: CYP26A1
3 Cross references
132 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSOTSG00005035756
Gene Symbol: CYP17A1
1 Cross references
210 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSOTSG00005017192
Gene Symbol: CYP19A1A
1 Cross references
246 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSOTSG00005002546
Gene Symbol: CYP26A1
1 Cross references
193 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSOTSG00005015397
Gene Symbol: CYP26A1
1 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).